Taboola Launches “News Feed”, Bringing Continuous-Scroll Experience to the Open Web, Recommending Content, Video, Products and More
Taboola, the leading content discovery platform, today launched the Taboola Feed - a continuous-scrolling feed that is a completely new content discovery experience for advertisers and publishers. Users will now be able to scroll infinitely after reading an article to discover various information including content, in-feed videos, products, app downloads, and more. Taboola also announced New York Daily News as the first publisher partner to test and implement Taboola Feed on its mobile and desktop pages.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170523006561/en/
New York Daily News first to implement Taboola Feed (Photo: Business Wire)
Taboola, which currently reaches 1 billion users a month globally, launched this technology to address content consumption habits derived from social media. Taboola Feed provides meaningful value to consumers who are already adapted to a similar experience on social networks, where they currently spend significant time. New York Daily News and other publishers using the Taboola Feed have already seen an increase in revenue and engagement simultaneously. In turn, Taboola Feed offers advertisers an opportunity to reach audiences in a targeted way -- leveraging the same formats that are available at scale on social networks but - adjacent to safe and quality editorial content.
The interface of the Feed surfaces ‘cards’ of different information and formats. The publisher has full control over which cards should be organic (recirculating their own editorial content) and which cards should be sponsored (paid by a marketer, sponsored content, in-feed video, products, apps, etc). The intent is to encourage readers to spend more time on site and within the publisher’s own environment, while continuing to serve content they may be interested in consuming next. Since employing the Taboola Feed on its pages last month, New York Daily News has seen an uplift in revenue of 26 percent, and engagement of 40 percent on mobile.
“User behavior evolves as digital environments evolve. Social media platforms have accustomed readers to the behavior of continuous-scrolling,” said Grant Whitmore, Executive Vice President, Digital, at New York Daily News. “The Taboola Feed mirrors that experience and brings an engaging environment to each article page that was previously only available on social media. We are excited to work with Taboola to pioneer the next evolution of the open web.”
“Imagine an experience like Instagram or Facebook that starts when an article ends on your favorite website. I could not be more excited to completely revolutionize our entire front-end product line on the 10th year of our journey. This marks the end of the “widget economy” and an opportunity to finally streamline the competing priorities publishers have waged for users’ attention throughout their site,” said Adam Singolda, CEO and founder of Taboola. “I’m particularly grateful to have the chance to work with Grant and the team at New York Daily News on this innovative revolution, and I’m confident the internet will look markedly different in years to come, starting with the change we have announced today.”
The new Taboola Feed experience will better enable brands to convey messaging to highly-valued customers on both desktop and mobile and engage in a brand-safe environment. Currently, while social platforms provide high engagement due to format and data, content marketers have very little choice of where their content and videos may appear. The Taboola Feed offers a similar integrated experience - including data to target the right audiences and global -- but placed next to premium and brand safe editorial content.
“I believe the user experience of the open web has to change, and become integrated, evolving from widgets appearing at the top, in mid article, along the right rail and at the bottom of article. - We have a lot to learn from social networks on that front,” continued Singolda. “I also believe advertisers need to have both amazing formats and the ability to target the right audience -- while appearing natively on the best sites and content in a safe environment. Taboola Feed is just the beginning in serving this mission - to deliver scale with brand safety.”
About Taboola
Taboola is the leading discovery platform, serving over 360 billion editorial and video recommendations to over 1 billion unique visitors every month on some of the Web’s most innovative publisher sites, including USA TODAY, Huffington Post, MSN, Business Insider, Chicago Tribune and The Weather Channel. Headquartered in New York City, Taboola also has offices in Los Angeles, London, Tel Aviv, New Delhi, Bangkok, São Paulo, Beijing, Shanghai, Seoul, Istanbul, Sydney and Tokyo. Publishers, marketers, and agencies leverage Taboola to retain users on their sites, monetize their traffic, and distribute their content to drive high-quality audiences. Learn more at www.taboola.com and follow @taboola on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523006561/en/
Contact information
Media Contact
Karen Germ, 480-332-7949
karen.g@taboola.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom